Heat waves have intensified since the 1960s, leaving older adults uniquely susceptible to heat-related illnesses, including hyperthermia and fluid-electrolyte imbalances. While clinicians recognize that certain medications increase heat vulnerability, the specific interplay between drug use and patient characteristics remains unclear. This scoping review, following the Joanna Briggs Institute framework for scoping reviews and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines, investigated the risk of heat-related illness associated with medication use in older adults to identify research gaps. Investigators queried four databases for English-language primary literature (2000–2025) based on predefined Population, Concept, and Context criteria. Additionally, a grey literature search mapped existing United States (U.S.) mitigation strategies. Two reviewers independently screened studies via Covidence, and one extracted data. Results included 61 primary studies and 41 grey literature sources. While epidemiological data confirm higher heat-related morbidity and mortality in older populations, few experimental studies evaluate medication’s specific role. Despite many public health efforts, specific, evidence-based guidance on managing drug-heat interactions is limited. Diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), anticholinergics, and antipsychotics were the medication classes most frequently associated with heat-related illness. This review underscores a critical need for research into the confluence of age, multimorbidity, and polypharmacy to inform future clinical mitigation and protect vulnerable populations.
4 November 2025 in International Journal of Pharmacy Practice
Objectives: To assess training, perceptions, and behaviours of pharmacy professionals and trainees about the relationship between climate change, environmental sustainability, and pharmacy practice. Methods: We conducted a cross-sectional survey-based study of a global sample of pharmacy professionals and trainees. Participants were recruited between June 2023 to March 2024 using professional networks and a snowball sampling approach. Descriptive statistics and content analysis were used to analyse survey results. Key findings: Four-hundred forty participants representing 24 countries responded to the survey. Participants identified as pharmacists, pharmacy students, or postgraduate pharmacy trainees practicing in a variety of settings. A majority reported substantial worry about the health impacts of climate change and had no prior training related to climate change. One-third of respondents indicated that pharmacists should address climate change and environmental issues. Many identified some action taken in their professional role. Barriers towards further action included lack of knowledge, time, and resources. Conclusions: Pharmacy professionals and trainees globally are concerned about the health impacts from climate change and the environment. Further resources, support, and education are needed to support pharmacists in caring for patients experiencing climate-health impacts and in connecting with other health professionals doing this critical work.
12 March 2024 in Journal of the American Pharmacists Association
Background: Residents of western US states face elevated fine particulate matter (PM 2.5 ) exposure from increasingly frequent and intense wildfires, raising concerns about cardiovascular risk. Whether short‐term PM 2.5 exposure increases odds of hospitalization or emergency care in patients with established atrial fibrillation (AF) remains unclear. Methods: Using 2021 Medicare data, we identified patients with established AF residing in western US states. Zip code–level daily PM 2.5 was estimated using a 1 km 2 geospatial model; high PM 2.5 was defined as ≥9.0 μg/m 3 . Odds ratios (ORs) for all‐cause and cardiovascular disease hospitalization and emergency department visits were estimated using conditional logistic regression at lag 0, 1, and 3 days, adjusting for extreme heat and public holidays. Results: The final cohort included 26 158 patients (mean age 79 ± 9.0 years) with established AF. Exposure to high levels of PM 2.5 was associated with 10% (95% CI, 1%–20%) increased odds of hospitalizations for cardiovascular disease. Specifically, high PM 2.5 was associated with 24% (95% CI, 3%–48%) increased odds of hospitalization and 34% (95% CI, 6%–70%) higher odds of emergency department visits for all AF‐related diagnoses. We did not observe significant interaction effects between PM 2.5 and extreme heat on the risk of hospitalization or emergency department visits for cardiovascular disease or AF. Conclusion: On days with elevated PM 2.5 levels, patients with AF were associated with higher odds of AF‐related or cardiovascular hospitalizations and emergency department visits, highlighting the need for targeted prevention strategies to protect vulnerable populations from the adverse effects of air pollution.